sirt2

SIRT2-IN-9 is a selective SRIT2 inhibitor with an IC50 value of 1.3 μM.SIRT2-IN-9 inhibits the proliferation of MCF-7 breast cancer cells.SIRT2-IN-9 can be used for cancer research.

Resveratrol (SRT 501) is a polyphenolic natural product, a plant antitoxin with antioxidant and chemopreventive activities. Resveratrol has a wide range of targets including COX, SIRT, LOC, etc. Resveratrol induces autophagy and apoptosis.

SRT 1720 dihydrochloride is a selective activator of SIRT1 (EC1.5: 0.16 μM) and shows less potent activities on SIRT2 (EC1.5: 37 μM) and SIRT3 (EC1.5: 300 μM).

RK-9123016 is a SIRT2 inhibitor. RK-9123016 increases the acetylation level of eukaryotic translation initiation factor 5A (eIF5A), a physiological substrate of SIRT2, and reduces cell viability of human breast cancer cells accompanied with a decrease in c-Myc expression.

Sirtinol is a selective SIRT1 2 inhibitor (IC50: 131 38 μM).

MIND4-19 is an inhibitor of SIRT2 with antitumor activity.

Thiomyristoyl is an effective and selective SIRT2 inhibitor (IC50: 28 nM). It inhibits SIRT1 (IC50: 98 μM) but no effect on SIRT3 even at 200 μM.

AGK2(IC50=3.5 μM) is an effective, and specific SIRT2 inhibitor.

Sirt2-IN-1 is an inhibitor of sirtuin 2 (IC50 = 163 nM).

SIRT2-IN-15 (compound 1) acts as both a deacetylase and deglycosylase inhibitor for SIRT2, exhibiting IC50 values of 7 μM and 37 μM, respectively.

**SIRT2-IN-14 (Compound 78)** is a selective SIRT2 inhibitor, demonstrating an IC50 value of 0.196 μM [1].

SIRT2-IN-17 (compound Z18) is a potent inhibitor of SIRT2, effectively reducing the expression of α-SMA and p-Smad2 3.

Sirt2-IN-5, a potent inhibitor of SIRT2, is specifically (2S)-2-[(Z)-4-(3-chlorophenyl)-3-methylbutanoylamino]-5-methylhexanoic acid [exact (1:1) of (2S,4R)-4-[(Z)-4-(3-chlorophenyl)-3-methylbutanoylamino]-5-methylhexanoic acid].

Sirt2-IN-6 is a potent and selective inhibitor of SIRT2 (IC50: 0.815 μM) and can be used to study cancer.

WAY-323061 is a SIRT2 inhibitor.

SIRT2-IN-16 (compound 17) is a SIRT2 inhibitor targeted at prostate-specific membrane antigen (PSMA).

SIRT2-IN-10 (Compound 12) is a potent SIRT2 inhibitor (IC50: 1.3 μM) useful for cancer and neurodegenerative disease research.

HSP70 SIRT2-IN-2 (Compounds 1a), a dual inhibitor of SIRT2 and HSP70, exhibits an IC50 of 45.1±5.0 μM against SIRT2 and demonstrates antitumor activity [1].

SIRT2-IN-11 (AEM1) is a selective inhibitor of SIRT2 with an inhibitory concentration (IC50) of 18.5 μM. It induces apoptosis in a p53-dependent manner, activates the expression of CDKN1A, PUMA, and NOXA, and enhances the acetylation of p53. This compound is utilized in the study of p53-associated cancers.

SIRT2-IN-13 (compound 7c) acts as an inhibitor of SIRT2, inducing apoptosis in cells. It selectively inhibits colon cancer and leukemia cells, causing a cell cycle arrest at the G2 phase.

HSP70 SIRT2-IN-1 (Compound 2a) serves as a dual inhibitor targeting both SIRT2 and HSP70, exhibiting an IC50 of 17.3±2.0 μM against SIRT2. This compound possesses antitumor activity [1].

PROTAC Sirt2 Degrader-1 is a SirReal-based PROTAC that acts as a Sirt2 degrader, composed of a highly potent and isotype-selective Sirt2 inhibitor, a linker, and a bona fide cereblon ligand for E3 ubiquitin ligase. PROTAC Sirt2 Degrader-1 shows an IC50 of 0.25 μM for Sirt2, with no effect on Sirt1 Sirt3 (IC50s > 100 μM)[1].

Sirt2-IN-7 (compound 22), a selective SIRT2 inhibitor with an IC50 of 178.2 nM and a Ki of 154.3 nM, is employed in cancer research [1].

Suramin Sodium Salt (BAY-205) is a sodium salt form of suramin, a polysulphonated naphthylurea with potential antineoplastic activity. Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration. This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis.